Subang Jaya, 26 October
Roche Services (ASIA PACIFIC) launch was officiated today by YB Dato’ Seri Ong Ka Chuan, Second Minister of International Trade and Industry at The Pinnacle Sunway building. “We are pleased to welcome the opening of Roche’s Global Shared Service Centre for the Asia Pacific region, an expansion of its current business portfolio in sales and distribution of pharmaceutical and diagnostic products and services in the country. Roche's investment demonstrates the company's continued confidence in Malaysia and is yet another testament to Malaysia's continued attraction as a preferred investment destination."
Dato' Seri Ong added, "Roche now joins more than 350 foreign and multinational companies who have set up regional and global shared services and outsourcing centres in Malaysia. This investment will also boost the growth of our services sector, which in turn will help provide numerous business opportunities to local companies. Moving forward, the Global Shared Service Centre in Malaysia will continue to grow its operations with an investment of RM110 million by the end of 2018.”
Also present at the ceremony were the Sunway Group’s Chairman and Founder, Tan Sri Dr. Jeffrey Cheah, the Swiss Ambassador to Malaysia, Michael Winzap and Chief Executive Officer of the Malaysian Investment Development Authority (MIDA), Dato’ Azman Mahmud.
Dr. Alan Hippe, Chief Financial and Information Officer of Roche Group said, “The creation of a Shared Service Centre for the Asia Pacific region in Malaysia will grant us access to a highly skilled workforce. This will allow us to reach economies of scale by centralising services in a single location. With this, our APAC affiliates can focus on the core business of bringing medicines and diagnostic tests to patients who need them.”
“Malaysia was chosen as the hub to create a Global Shared Service Centre for Asia Pacific region as it is strategically located in the heart of Southeast Asia, it has strong foreign direct investment policies, a dynamic business environment and a friendly competitive market,” Martin Kikstein, General Manager of Roche Services (ASIA PACIFIC) Sdn. Bhd. explained. “Furthermore, Malaysia has great infrastructure and a skilled workforce with broad language capabilities,” he added.
Welcoming Roche’s expansion here, Dato’ Azman Mahmud said, “Malaysia continues to attract companies around the world because we have clarity in our investment policies in addition to other competitive and comparative advantages. The quality employment and business linkages that Roche generates will further develop the healthcare industry in our country."
Dato’ Yasmin Mahmood, in her remarks, said, “Having Roche opening an office here speaks volumes of Malaysia’s readiness in supporting global demands. We are proud to have Roche as one of our MSC-status companies and we look forward to build a strong and fruitful relationship with them.”
Roche Services (ASIA PACIFIC) Sdn. Bhd. will create more than 200 positions for dedicated professionals in Malaysia over the next two years to work in an environment offering development opportunities across the Roche group. The Shared Service Centre covers 15 countries across the Asia Pacific region namely Australia, Bangladesh, China, Hong Kong, India, Indonesia, Korea, Malaysia, Myanmar, New Zealand, Philippines, Singapore, Taiwan, Thailand and Vietnam.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit: http://www.roche.com/